Frank Herting

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 359 citations

Pharmacy, Cell Biology, Immunology +17

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Klein, Werner Scheuer et al. · Clinical Cancer Research · 2013 · 199 citations

Medicine, Cancer Biology, Oncology +17

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker, Katharina Wartha, Thomas Friess et al. · Molecular Cancer Therapeutics · 2016 · 131 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +17

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Stéphane Dalle, Lina Reslan, Timothee Besseyre de Horts et al. · Molecular Cancer Therapeutics · 2011 · 128 citations · Full text

Pharmacy, Immunology, Oncology +16

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Abhishek S. Kashyap, Martina Schmittnaegel, Nicolò Rigamonti et al. · Proceedings of the National Academy of Sciences · 2019 · 89 citations · Full text

Medicine, Immunology, Oncology +17